AstraZeneca PLC (AZN)vsMiniMed Group, Inc. Common Stock (MMED)
AZN
AstraZeneca PLC
$157.97
-1.49%
HEALTHCARE · Cap: $263.09B
MMED
MiniMed Group, Inc. Common Stock
$18.99
-0.58%
HEALTHCARE · Cap: $5.17B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1878% more annual revenue ($61.37B vs $3.10B). AZN leads profitability with a 17.0% profit margin vs -10.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
MMED
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$157.97
$38.96 discount
Intrinsic value data unavailable for MMED.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
15.6% revenue growth
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
ROE of 0.0% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : MMED
The strongest argument for MMED centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : MMED
The primary concerns for MMED are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a mature stock while MMED is a growth play — different risk/reward profiles.
MMED is growing revenue faster at 15.6% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 37/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
MiniMed Group, Inc. Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?